Pfizer Voluntarily Withdraws All Lots Of Its OXBRYTA Sickle Cell Disease Treatment From Worldwide Markets; Decision Based On The Totality Of Clinical Data That Now Indicates The Overall Benefit Of OXBRYTA No Longer Outweighs The Risk In The Approved Sickle Cell Patient Population
Portfolio Pulse from Benzinga Newsdesk
Pfizer has decided to voluntarily withdraw all lots of its OXBRYTA sickle cell disease treatment from global markets. This decision is based on clinical data indicating that the benefits of OXBRYTA no longer outweigh the risks for the approved patient population.
September 25, 2024 | 9:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pfizer is withdrawing its OXBRYTA treatment for sickle cell disease from the market due to unfavorable clinical data. This could impact Pfizer's stock as it may affect revenue and investor confidence.
The withdrawal of OXBRYTA, a treatment for sickle cell disease, suggests potential revenue loss and may affect investor confidence in Pfizer's product pipeline. This decision is based on clinical data showing that the risks of the drug outweigh its benefits, which could lead to a negative short-term impact on Pfizer's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100